img

Global Radionuclide Drug Conjugates (RDC) Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Radionuclide Drug Conjugates (RDC) Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal Radionuclide Drug Conjugates (RDC) Market
Global Radionuclide Drug Conjugates (RDC) market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Radionuclide Drug Conjugates (RDC) industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.
According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.
At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.
According to different targeting ligands, RDC can be subdivided intoantibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).
According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.
Report Covers
This report presents an overview of global Radionuclide Drug Conjugates (RDC) market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Radionuclide Drug Conjugates (RDC) market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Uihc Pet Imaging
Grand Pharma
BoomRay Pharmaceuticals
SmartNuclide Biopharma
Hengrui Medicine
Yunnan Baiyao Group
Sinotau
Hexin Pharmaceutical
Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
Segment by Type
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)

Segment by Application


Neuroendocrine Tumors
Prostate Cancer
Renal Cell Carcinoma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Radionuclide Drug Conjugates (RDC) introduction, etc. Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Radionuclide Drug Conjugates (RDC)
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Antibody Radionuclide Conjugates (ARC)
1.2.3 Peptide Radionuclide Conjugates (PRC)
1.2.4 Small Molecular Radionuclide Conjugates (SMRC)
1.3 Market by Application
1.3.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Neuroendocrine Tumors
1.3.3 Prostate Cancer
1.3.4 Renal Cell Carcinoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radionuclide Drug Conjugates (RDC) Market Perspective (2018-2033)
2.2 Global Radionuclide Drug Conjugates (RDC) Growth Trends by Region
2.2.1 Radionuclide Drug Conjugates (RDC) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Radionuclide Drug Conjugates (RDC) Historic Market Size by Region (2018-2023)
2.2.3 Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2024-2033)
2.3 Radionuclide Drug Conjugates (RDC) Market Dynamics
2.3.1 Radionuclide Drug Conjugates (RDC) Industry Trends
2.3.2 Radionuclide Drug Conjugates (RDC) Market Drivers
2.3.3 Radionuclide Drug Conjugates (RDC) Market Challenges
2.3.4 Radionuclide Drug Conjugates (RDC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Radionuclide Drug Conjugates (RDC) by Players
3.1.1 Global Radionuclide Drug Conjugates (RDC) Revenue by Players (2018-2023)
3.1.2 Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Players (2018-2023)
3.2 Global Radionuclide Drug Conjugates (RDC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Radionuclide Drug Conjugates (RDC), Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio
3.4.1 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radionuclide Drug Conjugates (RDC) Revenue in 2022
3.5 Global Key Players of Radionuclide Drug Conjugates (RDC) Head office and Area Served
3.6 Global Key Players of Radionuclide Drug Conjugates (RDC), Product and Application
3.7 Global Key Players of Radionuclide Drug Conjugates (RDC), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Radionuclide Drug Conjugates (RDC) Breakdown Data by Type
4.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Type (2018-2023)
4.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Type (2024-2033)
5 Radionuclide Drug Conjugates (RDC) Breakdown Data by Application
5.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Application (2018-2023)
5.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
6.2 North America Radionuclide Drug Conjugates (RDC) Market Size by Type
6.2.1 North America Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023)
6.2.2 North America Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033)
6.2.3 North America Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
6.3 North America Radionuclide Drug Conjugates (RDC) Market Size by Application
6.3.1 North America Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023)
6.3.2 North America Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033)
6.3.3 North America Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
6.4 North America Radionuclide Drug Conjugates (RDC) Market Size by Country
6.4.1 North America Radionuclide Drug Conjugates (RDC) Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
6.4.3 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
7.2 Europe Radionuclide Drug Conjugates (RDC) Market Size by Type
7.2.1 Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023)
7.2.2 Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033)
7.2.3 Europe Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
7.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Application
7.3.1 Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023)
7.3.2 Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033)
7.3.3 Europe Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
7.4 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country
7.4.1 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
7.4.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
8.2 China Radionuclide Drug Conjugates (RDC) Market Size by Type
8.2.1 China Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023)
8.2.2 China Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033)
8.2.3 China Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
8.3 China Radionuclide Drug Conjugates (RDC) Market Size by Application
8.3.1 China Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023)
8.3.2 China Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033)
8.3.3 China Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
9.2 Asia Radionuclide Drug Conjugates (RDC) Market Size by Type
9.2.1 Asia Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023)
9.2.2 Asia Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033)
9.2.3 Asia Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
9.3 Asia Radionuclide Drug Conjugates (RDC) Market Size by Application
9.3.1 Asia Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023)
9.3.2 Asia Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033)
9.3.3 Asia Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
9.4 Asia Radionuclide Drug Conjugates (RDC) Market Size by Region
9.4.1 Asia Radionuclide Drug Conjugates (RDC) Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2023)
9.4.3 Asia Radionuclide Drug Conjugates (RDC) Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Type
10.2.1 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Application
10.3.1 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country
10.4.1 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Details
11.1.2 POINT Biopharma Business Overview
11.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.1.4 POINT Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.1.5 POINT Biopharma Recent Developments
11.2 Telix
11.2.1 Telix Company Details
11.2.2 Telix Business Overview
11.2.3 Telix Radionuclide Drug Conjugates (RDC) Introduction
11.2.4 Telix Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.2.5 Telix Recent Developments
11.3 ITM AG
11.3.1 ITM AG Company Details
11.3.2 ITM AG Business Overview
11.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Introduction
11.3.4 ITM AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.3.5 ITM AG Recent Developments
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Introduction
11.4.4 Bayer AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.4.5 Bayer AG Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Radionuclide Drug Conjugates (RDC) Introduction
11.5.4 Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.5.5 Novartis Recent Developments
11.6 Lantheus
11.6.1 Lantheus Company Details
11.6.2 Lantheus Business Overview
11.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Introduction
11.6.4 Lantheus Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.6.5 Lantheus Recent Developments
11.7 Curium Pharma
11.7.1 Curium Pharma Company Details
11.7.2 Curium Pharma Business Overview
11.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.7.4 Curium Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.7.5 Curium Pharma Recent Developments
11.8 Uihc Pet Imaging
11.8.1 Uihc Pet Imaging Company Details
11.8.2 Uihc Pet Imaging Business Overview
11.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Introduction
11.8.4 Uihc Pet Imaging Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.8.5 Uihc Pet Imaging Recent Developments
11.9 Grand Pharma
11.9.1 Grand Pharma Company Details
11.9.2 Grand Pharma Business Overview
11.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.9.4 Grand Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.9.5 Grand Pharma Recent Developments
11.10 BoomRay Pharmaceuticals
11.10.1 BoomRay Pharmaceuticals Company Details
11.10.2 BoomRay Pharmaceuticals Business Overview
11.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Introduction
11.10.4 BoomRay Pharmaceuticals Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.10.5 BoomRay Pharmaceuticals Recent Developments
11.11 SmartNuclide Biopharma
11.11.1 SmartNuclide Biopharma Company Details
11.11.2 SmartNuclide Biopharma Business Overview
11.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.11.4 SmartNuclide Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.11.5 SmartNuclide Biopharma Recent Developments
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Details
11.12.2 Hengrui Medicine Business Overview
11.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Introduction
11.12.4 Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.12.5 Hengrui Medicine Recent Developments
11.13 Yunnan Baiyao Group
11.13.1 Yunnan Baiyao Group Company Details
11.13.2 Yunnan Baiyao Group Business Overview
11.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Introduction
11.13.4 Yunnan Baiyao Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.13.5 Yunnan Baiyao Group Recent Developments
11.14 Sinotau
11.14.1 Sinotau Company Details
11.14.2 Sinotau Business Overview
11.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Introduction
11.14.4 Sinotau Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.14.5 Sinotau Recent Developments
11.15 Hexin Pharmaceutical
11.15.1 Hexin Pharmaceutical Company Details
11.15.2 Hexin Pharmaceutical Business Overview
11.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Introduction
11.15.4 Hexin Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.15.5 Hexin Pharmaceutical Recent Developments
11.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
11.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Details
11.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
11.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Introduction
11.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Antibody Radionuclide Conjugates (ARC)
Table 3. Key Players of Peptide Radionuclide Conjugates (PRC)
Table 4. Key Players of Small Molecular Radionuclide Conjugates (SMRC)
Table 5. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 6. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2018-2023)
Table 9. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2024-2033)
Table 11. Radionuclide Drug Conjugates (RDC) Market Trends
Table 12. Radionuclide Drug Conjugates (RDC) Market Drivers
Table 13. Radionuclide Drug Conjugates (RDC) Market Challenges
Table 14. Radionuclide Drug Conjugates (RDC) Market Restraints
Table 15. Global Radionuclide Drug Conjugates (RDC) Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Radionuclide Drug Conjugates (RDC) Revenue Share by Players (2018-2023)
Table 17. Global Top Radionuclide Drug Conjugates (RDC) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugates (RDC) as of 2022)
Table 18. Global Radionuclide Drug Conjugates (RDC) Industry Ranking 2021 VS 2022 VS 2023
Table 19. Global 5 Largest Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue (CR5 and HHI) & (2018-2023)
Table 20. Global Key Players of Radionuclide Drug Conjugates (RDC), Headquarters and Area Served
Table 21. Global Key Players of Radionuclide Drug Conjugates (RDC), Product and Application
Table 22. Global Key Players of Radionuclide Drug Conjugates (RDC), Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Type (2018-2023)
Table 26. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Type (2024-2033)
Table 28. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Radionuclide Drug Conjugates (RDC) Revenue Share by Application (2018-2023)
Table 30. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Radionuclide Drug Conjugates (RDC) Revenue Share by Application (2024-2033)
Table 32. North America Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (US$ Million)
Table 33. North America Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033) & (US$ Million)
Table 34. North America Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (US$ Million)
Table 35. North America Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033) & (US$ Million)
Table 36. North America Radionuclide Drug Conjugates (RDC) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033) & (US$ Million)
Table 39. Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (US$ Million)
Table 40. Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033) & (US$ Million)
Table 41. Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (US$ Million)
Table 42. Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033) & (US$ Million)
Table 43. Europe Radionuclide Drug Conjugates (RDC) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023) & (US$ Million)
Table 45. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033) & (US$ Million)
Table 46. China Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (US$ Million)
Table 47. China Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033) & (US$ Million)
Table 48. China Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (US$ Million)
Table 49. China Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033) & (US$ Million)
Table 50. Asia Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (US$ Million)
Table 51. Asia Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033) & (US$ Million)
Table 52. Asia Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (US$ Million)
Table 53. Asia Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033) & (US$ Million)
Table 54. Asia Radionuclide Drug Conjugates (RDC) Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 55. Asia Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2023) & (US$ Million)
Table 56. Asia Radionuclide Drug Conjugates (RDC) Market Size by Region (2024-2033) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Type (2024-2033) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Application (2024-2033) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 62. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033) & (US$ Million)
Table 64. POINT Biopharma Company Details
Table 65. POINT Biopharma Business Overview
Table 66. POINT Biopharma Radionuclide Drug Conjugates (RDC) Product
Table 67. POINT Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 68. POINT Biopharma Recent Developments
Table 69. Telix Company Details
Table 70. Telix Business Overview
Table 71. Telix Radionuclide Drug Conjugates (RDC) Product
Table 72. Telix Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 73. Telix Recent Developments
Table 74. ITM AG Company Details
Table 75. ITM AG Business Overview
Table 76. ITM AG Radionuclide Drug Conjugates (RDC) Product
Table 77. ITM AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 78. ITM AG Recent Developments
Table 79. Bayer AG Company Details
Table 80. Bayer AG Business Overview
Table 81. Bayer AG Radionuclide Drug Conjugates (RDC) Product
Table 82. Bayer AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 83. Bayer AG Recent Developments
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Radionuclide Drug Conjugates (RDC) Product
Table 87. Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 88. Novartis Recent Developments
Table 89. Lantheus Company Details
Table 90. Lantheus Business Overview
Table 91. Lantheus Radionuclide Drug Conjugates (RDC) Product
Table 92. Lantheus Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 93. Lantheus Recent Developments
Table 94. Curium Pharma Company Details
Table 95. Curium Pharma Business Overview
Table 96. Curium Pharma Radionuclide Drug Conjugates (RDC) Product
Table 97. Curium Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 98. Curium Pharma Recent Developments
Table 99. Uihc Pet Imaging Company Details
Table 100. Uihc Pet Imaging Business Overview
Table 101. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product
Table 102. Uihc Pet Imaging Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 103. Uihc Pet Imaging Recent Developments
Table 104. Grand Pharma Company Details
Table 105. Grand Pharma Business Overview
Table 106. Grand Pharma Radionuclide Drug Conjugates (RDC) Product
Table 107. Grand Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 108. Grand Pharma Recent Developments
Table 109. BoomRay Pharmaceuticals Company Details
Table 110. BoomRay Pharmaceuticals Business Overview
Table 111. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product
Table 112. BoomRay Pharmaceuticals Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 113. BoomRay Pharmaceuticals Recent Developments
Table 114. SmartNuclide Biopharma Company Details
Table 115. SmartNuclide Biopharma Business Overview
Table 116. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product
Table 117. SmartNuclide Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 118. SmartNuclide Biopharma Recent Developments
Table 119. Hengrui Medicine Company Details
Table 120. Hengrui Medicine Business Overview
Table 121. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product
Table 122. Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 123. Hengrui Medicine Recent Developments
Table 124. Yunnan Baiyao Group Company Details
Table 125. Yunnan Baiyao Group Business Overview
Table 126. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product
Table 127. Yunnan Baiyao Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 128. Yunnan Baiyao Group Recent Developments
Table 129. Sinotau Company Details
Table 130. Sinotau Business Overview
Table 131. Sinotau Radionuclide Drug Conjugates (RDC) Product
Table 132. Sinotau Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 133. Sinotau Recent Developments
Table 134. Hexin Pharmaceutical Company Details
Table 135. Hexin Pharmaceutical Business Overview
Table 136. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product
Table 137. Hexin Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 138. Hexin Pharmaceutical Recent Developments
Table 139. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Details
Table 140. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
Table 141. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product
Table 142. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 143. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Developments
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Radionuclide Drug Conjugates (RDC) Market Share by Type: 2022 VS 2033
Figure 3. Antibody Radionuclide Conjugates (ARC) Features
Figure 4. Peptide Radionuclide Conjugates (PRC) Features
Figure 5. Small Molecular Radionuclide Conjugates (SMRC) Features
Figure 6. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 7. Global Radionuclide Drug Conjugates (RDC) Market Share by Application: 2022 VS 2033
Figure 8. Neuroendocrine Tumors Case Studies
Figure 9. Prostate Cancer Case Studies
Figure 10. Renal Cell Carcinoma Case Studies
Figure 11. Radionuclide Drug Conjugates (RDC) Report Years Considered
Figure 12. Global Radionuclide Drug Conjugates (RDC) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Radionuclide Drug Conjugates (RDC) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Radionuclide Drug Conjugates (RDC) Market Share by Region: 2022 VS 2033
Figure 15. Global Radionuclide Drug Conjugates (RDC) Market Share by Players in 2022
Figure 16. Global Top Radionuclide Drug Conjugates (RDC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugates (RDC) as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue in 2022
Figure 18. North America Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
Figure 20. North America Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
Figure 21. North America Radionuclide Drug Conjugates (RDC) Market Share by Country (2018-2033)
Figure 22. United States Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Radionuclide Drug Conjugates (RDC) Market Size YoY (2018-2033) & (US$ Million)
Figure 25. Europe Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
Figure 26. Europe Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
Figure 27. Europe Radionuclide Drug Conjugates (RDC) Market Share by Country (2018-2033)
Figure 28. Germany Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. France Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. U.K. Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Italy Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Russia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Nordic Countries Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. China Radionuclide Drug Conjugates (RDC) Market Size YoY (2018-2033) & (US$ Million)
Figure 35. China Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
Figure 36. China Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
Figure 37. Asia Radionuclide Drug Conjugates (RDC) Market Size YoY (2018-2033) & (US$ Million)
Figure 38. Asia Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
Figure 39. Asia Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
Figure 40. Asia Radionuclide Drug Conjugates (RDC) Market Share by Region (2018-2033)
Figure 41. Japan Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. South Korea Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. China Taiwan Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. India Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Australia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Size YoY (2018-2033) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Share by Type (2018-2033)
Figure 49. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Share by Application (2018-2033)
Figure 50. Middle East, Africa, and Latin America Radionuclide Drug Conjugates (RDC) Market Share by Country (2018-2033)
Figure 51. Brazil Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. Mexico Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Turkey Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Saudi Arabia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Israel Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. GCC Countries Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. POINT Biopharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 58. Telix Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 59. ITM AG Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 60. Bayer AG Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 61. Novartis Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 62. Lantheus Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 63. Curium Pharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 64. Uihc Pet Imaging Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 65. Grand Pharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 66. BoomRay Pharmaceuticals Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 67. SmartNuclide Biopharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 68. Hengrui Medicine Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 69. Yunnan Baiyao Group Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 70. Sinotau Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 71. Hexin Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 72. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries